GKOS GLAUKOS Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1192448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.9%
TTM net income YoY-93.8%
TTM EPS YoY-91.6%
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-25.5%
Net margin-24.6%
FCF margin5.2%
EBITDA margin-19.5%
Returns
ROE-22.8%
ROA-17.2%
ROIC (approx.)-22.8%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.00x
Current ratio4.57x
Interest coverage-36.57x
Cash quality & payout
Operating cash flow / net income-0.28x
Accruals ratio-22.0%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $507.44M | $383.48M | $314.71M | $282.86M | $294.01M |
| Cost of revenue | $111.81M | $94.03M | $75.58M | $68.98M | $66.63M |
| Gross profit | $282.76M | $289.45M | $239.14M | $213.88M | $227.38M |
| R&D expense | $150.61M | $136.43M | $138.77M | $123.27M | $101.00M |
| SG&A expense | $331.75M | $261.17M | $224.07M | $192.93M | $179.26M |
| Operating income | -$199.60M | -$122.37M | -$128.70M | -$82.31M | -$32.87M |
| Interest expense | $4.63M | $10.04M | $13.63M | $13.72M | $13.37M |
| Pretax income | -$193.04M | -$145.60M | -$133.73M | -$98.43M | -$49.27M |
| Income tax | -$5.35M | $771,000 | $934,000 | $766,000 | $326,000 |
| Net income | -$187.69M | -$146.37M | -$134.66M | -$99.19M | -$49.59M |
| EBITDA | -$161.51M | -$86.72M | -$95.05M | -$50.74M | -$3.21M |
| EPS (basic) | -3.28 | -2.77 | -2.78 | -2.09 | -1.07 |
| EPS (diluted) | -3.28 | -2.77 | -2.78 | -2.09 | -1.07 |
| Weighted avg. shares (diluted) | 57.19M | 52.76M | 48.43M | 47.44M | 46.42M |
| Balance sheet | |||||
| Cash & equivalents | $90.81M | $174.36M | $93.47M | $126.60M | $110.12M |
| Receivables | $108.61M | $60.74M | $39.85M | $36.07M | $33.44M |
| Inventory | $63.56M | $57.68M | $41.99M | $37.84M | $23.01M |
| Current assets | $474.98M | $449.79M | $395.46M | $443.86M | $486.13M |
| PP&E, net | $113.25M | $97.87M | $103.21M | $94.40M | $68.97M |
| Goodwill | $66.71M | $66.13M | $66.13M | $66.13M | $66.13M |
| Intangibles | $141.92M | $263.44M | $282.96M | $307.87M | $332.78M |
| Total assets | $893.49M | $974.76M | $940.41M | $1.00B | $1.05B |
| Current liabilities | $101.28M | $75.12M | $74.01M | $72.36M | $63.36M |
| Total liabilities | $237.33M | $207.82M | $478.65M | $472.38M | $462.55M |
| Shareholders' equity | $656.15M | $766.93M | $461.77M | $530.00M | $587.15M |
| Shares outstanding | 57.51M | 56.44M | 49.12M | 47.75M | 46.97M |
| Cash flow statement | |||||
| Operating cash flow | -$14.79M | -$61.32M | -$57.76M | -$33.08M | $24.71M |
| Capital expenditure | $7.67M | $6.30M | $20.25M | $30.27M | $47.78M |
| Free cash flow | -$22.45M | -$67.62M | -$78.01M | -$63.35M | -$23.08M |
| Investing cash flow | -$77.61M | $47.83M | $14.10M | $44.78M | -$58.23M |
| Financing cash flow | $11.89M | $91.54M | $15.04M | $6.25M | $39.26M |
| Depreciation & amortization | $38.09M | $35.65M | $33.65M | $31.58M | $29.66M |
| Stock-based compensation | $63.22M | $50.21M | $43.53M | $38.56M | $30.15M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.